KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Other Non Operating Income (2016 - 2020)

Aurinia Pharmaceuticals filings provide 3 years of Other Non Operating Income readings, the most recent being -$2.6 million for Q3 2020.

  • On a quarterly basis, Other Non Operating Income fell 157.6% to -$2.6 million in Q3 2020 year-over-year; TTM through Sep 2020 was -$57.5 million, a 184.19% decrease, with the full-year FY2019 number at -$41.1 million, down 313.14% from a year prior.
  • Other Non Operating Income hit -$2.6 million in Q3 2020 for Aurinia Pharmaceuticals, down from $3.0 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $4.5 million in Q3 2019 to a low of -$48.0 million in Q4 2019.
  • Median Other Non Operating Income over the past 3 years was -$3.7 million (2018), compared with a mean of -$9.7 million.
  • The widest YoY moves for Other Non Operating Income: up 572.32% in 2020, down 157.6% in 2020.
  • Aurinia Pharmaceuticals' Other Non Operating Income stood at -$19.3 million in 2018, then plummeted by 148.44% to -$48.0 million in 2019, then surged by 94.58% to -$2.6 million in 2020.
  • The last three reported values for Other Non Operating Income were -$2.6 million (Q3 2020), $3.0 million (Q2 2020), and -$9.8 million (Q1 2020) per Business Quant data.